Q4 2021 Holdings
Filed 2022-02-14 | 121 holdings | $6.4B | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| BeiGene, Ltd.(ONC) | SPONSORED ADR | 07725L102 | $3.2B | 11,668,897 | 49.7% |
| Acadia Pharmaceuticals Inc.(ACAD) | COM | 004225108 | $978.2M | 41,910,704 | 15.4% |
| BioMarin Pharmaceutical Inc.(BMRN) | COM | 09061G101 | $673.3M | 7,620,494 | 10.6% |
| Ascendis Pharma A/S(ASND) | SPONSORED ADR | 04351P101 | $611.0M | 4,541,604 | 9.6% |
| argenx SE(ARGX) | SPONSORED ADR | 04016X101 | $392.1M | 1,119,557 | 6.2% |
| BioCryst Pharmaceuticals, Inc.(BCRX) | COM | 09058V103 | $176.0M | 12,710,818 | 2.8% |
| AbCellera Biologics Inc.(ABCL) | COM | 00288U106 | $149.4M | 10,450,180 | 2.4% |
| Cerus Corporation(CERS) | COM | 157085101 | $93.4M | 13,713,195 | 1.5% |
| Adaptimmune Therapeutics plc(ADAPY) | SPONSORED ADR | 00653A107 | $36.9M | 9,830,877 | 0.6% |
| Crinetics Pharmaceuticals, Inc.(CRNX) | COM | 22663K107 | $23.5M | 827,480 | 0.4% |
| Axsome Therapeutics, Inc.(AXSM) | COM | 05464T104 | $23.1M | 610,970 | 0.4% |
| Altimmune, Inc.(ALT) | COM | 02155H200 | $9.8M | 1,072,038 | 0.2% |
| Seagen Inc.(SGENUSD) | COM | 81181C104 | $7.2M | 46,893,364 | 0.1% |
| Alector, Inc.(ALEC) | COM | 014442107 | $4.9M | 239,228 | 0.1% |
| aTyr Pharma, Inc.(ATYR) | COM | 002120202 | $4.7M | 625,000 | 0.1% |
| Biomea Fusion, Inc.(BMEA) | COM | 09077A106 | $3.9M | 524,617 | 0.1% |
| Cabaletta Bio, Inc.(CABA) | COM | 12674W109 | $2.5M | 662,063 | 0.0% |
| Incyte Corporation(INCY) | COM | 45337C102 | $2.5M | 33,618,063 | 0.0% |
| Kodiak Sciences Inc.(KOD) | COM | 50015M109 | $1.2M | 14,681,304 | 0.0% |
| Mirati Therapeutics, Inc.(MRTXEUR) | COM | 60468T105 | $206.8K | 1,409,784 | 0.0% |
| Kymera Therapeutics, Inc.(KYMR) | COM | 501575104 | $151.4K | 2,384,742 | 0.0% |
| Invitae Corporation(NVTA1EUR) | COM | 46185L103 | $150.8K | 9,873,488 | 0.0% |
| Madrigal Pharmaceuticals, Inc.(MDGL) | COM | 558868105 | $127.0K | 1,499,213 | 0.0% |
| Prelude Therapeutics Inc.(PRLD) | COM | 74065P101 | $126.0K | 10,123,824 | 0.0% |
| Legend Biotech Corporation(LEGN) | SPONSORED ADS | 52490G102 | $116.0K | 2,489,003 | 0.0% |
| Pacific Biosciences of California, Inc.(PACB) | COM | 69404D108 | $111.4K | 5,444,963 | 0.0% |
| Global Blood Therapeutics, Inc. | COM | 37890U108 | $97.0K | 3,314,765 | 0.0% |
| IGM Biosciences, Inc.(1K0) | COM | 449585108 | $92.6K | 3,156,102 | 0.0% |
| Immunocore Holdings plc(IMCR) | ADS | 45258D105 | $86.3K | 2,520,730 | 0.0% |
| Travere Therapeutics, Inc.(TVTX) | COM | 89422G107 | $82.8K | 2,669,054 | 0.0% |
| Entrada Therapeutics, Inc.(TRDA) | COM | 29384C108 | $80.5K | 4,704,419 | 0.0% |
| Heron Therapeutics, Inc.(HRTX) | COM | 427746102 | $74.2K | 8,131,678 | 0.0% |
| Amarin Corporation plc | SPONSORED ADR | 023111206 | $71.3K | 21,169,805 | 0.0% |
| Nurix Therapeutics, Inc.(NRIX) | COM | 67080M103 | $71.0K | 2,454,082 | 0.0% |
| Instil Bio, Inc. | COM | 45783C101 | $66.6K | 3,893,700 | 0.0% |
| Merus N.V. | COM | N5749R100 | $64.8K | 2,037,469 | 0.0% |
| Horizon Therapeutics Public Ltd Co | SHS | G46188101 | $64.6K | 599,110 | 0.0% |
| Immatics N.V.(IMTX) | SHS | N44445109 | $59.5K | 4,423,731 | 0.0% |
| ChemoCentryx, Inc.(CCXIEUR) | COM | 16383L106 | $59.4K | 1,631,266 | 0.0% |
| Insmed Incorporated(INSM) | COM PAR $.01 | 457669307 | $58.7K | 2,156,001 | 0.0% |
| Neurocrine Biosciences, Inc.(NBIX) | COM | 64125C109 | $57.7K | 676,975 | 0.0% |
| Krystal Biotech, Inc.(KRYS) | COM | 501147102 | $56.5K | 807,735 | 0.0% |
| Verve Therapeutics, Inc. | COM | 92539P101 | $52.2K | 1,416,530 | 0.0% |
| Apellis Pharmaceuticals, Inc. | Note 3.5% 9/15/2026 | 03753UAB2 | $48.0K | $31,754,000 | 0.0% |
| Verastem, Inc. | COM | 92337C104 | $44.1K | 21,491,630 | 0.0% |
| Insmed Incorporated | Note 0.75% 6/1/2028 | 457669AB5 | $43.3K | $40,000,000 | 0.0% |
| Sarepta Therapeutics, Inc. | DBCV 1.5% 11/15/2024 | 803607AB6 | $42.7K | $29,174,000 | 0.0% |
| Rhythm Pharmaceuticals, Inc.(RYTM) | COM | 76243J105 | $38.6K | 3,863,239 | 0.0% |
| Chinook Therapeutics, Inc.(290A) | COM | 16961L106 | $38.1K | 2,334,102 | 0.0% |
| Ultragenyx Pharmaceutical Inc.(RARE) | COM | 90400D108 | $37.4K | 444,444 | 0.0% |